Identification of BGN and THBS2 as metastasis‐specific biomarkers and poor survival key regulators in human colon cancer by integrated analysis
Clinical and Translational Medicine2022Vol. 12(11), pp. e973–e973
Citations Over TimeTop 10% of 2022 papers
Zhicheng He, Jian Lin, Cheng Chen, Yuanzhi Chen, Shuting Yang, Xiang‐Hai Cai, Yingying He, Shubai Liu
Abstract
CRC metastatic progression, EMT phenotypic transition and poor survival time have been linked to BGN and THBS2. They could be utilized as potential diagnostic and therapeutic targets for colon cancer metastatic patients with a better prognosis.
Related Papers
- → Interstitial Lung Disease Associated with Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin(2010)4 cited
- → FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer(2012)2 cited
- The Efficacy and Toxicity of FOLFOX Regimen（A Combination of Leucovorin and Fluorouracil with Oxaliplatin）as First-Line Treatment of Metastatic Colorectal Cancer(2009)
- → Adjuvant FOLFOX Treatment for Stage III Colorectal Cancer: Why Patients Quit FOLFOX?(2017)
- Oxaliplatin, 5-Fluorouracil, Leucovorin 복합항암화학요법 중에 발생한 간질성 폐질환 1예(2010)